Notice of NEI Participation in PAR-19-158 "Bioengineering Research Grants (R01 Clinical Trial Not Allowed)"

Notice Number: NOT-EY-19-014

Key Dates
Release Date: March 5, 2019

Related Announcements

Issued by
National Eye Institute (NEI)


The purpose of this Notice is to inform potential applicants that the National Eye Institute (NEI) will participate, effective immediately, in PAR-19-158, "Bioengineering Research Grants (R01 Clinical Trial Not Allowed)"

The following sections of PAR-19-158 (shown in italics) have been updated to reflect the NEI's participation in this Funding Opportunity Announcement (FOA).

Components of Participating Organizations

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Cancer Institute (NCI)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Environmental Health Sciences (NIEHS)

National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Allergy and Infectious Diseases (NIAID)

National Institute on Aging (NIA)

National Eye Institute (NEI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.286; 93.399; 93.396; 93.395; 93.394; 93.393; 93.121; 93.853; 93.113; 93.866; 93.273; 93.846, 93.855, 93.867

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Institute statements of interest:

NEI: The National Eye Institute (NEI) supports a broad range of basic and clinical research, clinical trials, epidemiologic studies related to health and disease in the eye and visual system.Research proposed should address a significant aspect of the leading causes of blindness and impaired vision, mechanisms of visual function, preservation of sight, or the special health problems and requirements of the blind.

All other aspects of this FOA remain unchanged.


Please direct all inquiries to:

Jerome Wujek
National Eye Institute (NEI)
Telephone: (301) 451-2020